Marker Historical Income Statement
| MRKR Stock | USD 1.33 0.04 2.92% |
Historical analysis of Marker Therapeutics income statement accounts such as Total Revenue of 4 M can show how well Marker Therapeutics performed in making a profits. Evaluating Marker Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Marker Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Marker Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Marker Therapeutics is a good buy for the upcoming year.
Marker |
About Marker Income Statement Analysis
Marker Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Marker Therapeutics shareholders. The income statement also shows Marker investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Marker Therapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Marker Therapeutics. It is also known as Marker Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Marker Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Marker Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Marker Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. To learn how to invest in Marker Stock, please use our How to Invest in Marker Therapeutics guide.At this time, Marker Therapeutics' Depreciation And Amortization is relatively stable compared to the past year. As of 03/28/2025, Total Revenue is likely to grow to about 4 M, while Selling General Administrative is likely to drop slightly above 5.6 M.
| 2022 | 2024 | 2025 (projected) | Reconciled Depreciation | 3.7M | 4.2M | 2.3M | Interest Income | 248.1K | 402.5K | 291.5K |
Marker Therapeutics income statement Correlations
Click cells to compare fundamentals
Marker Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Marker Therapeutics income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Depreciation And Amortization | 1.1M | 3.2M | 3.7M | 2.8M | 2.5M | 2.6M | |
| Selling General Administrative | 10.5M | 12.9M | 12.8M | 7.5M | 8.6M | 5.6M | |
| Total Revenue | 466.8K | 1.2M | 9.0M | 3.3M | 3.8M | 4.0M | |
| Gross Profit | (18.4M) | (1.9M) | 5.3M | (7.1M) | (6.4M) | (6.1M) | |
| Other Operating Expenses | 29.4M | 40.7M | 39.0M | 17.9M | 20.6M | 16.1M | |
| Operating Income | (28.9M) | (39.5M) | (29.9M) | (14.6M) | (13.1M) | (13.8M) | |
| Ebit | (28.7M) | (39.5M) | (23.5M) | (14.6M) | (13.1M) | (13.8M) | |
| Research Development | 18.9M | 27.8M | 26.1M | 10.4M | 12.0M | 10.9M | |
| Ebitda | (27.6M) | (36.3M) | (19.8M) | (11.8M) | (10.6M) | (11.1M) | |
| Cost Of Revenue | 18.9M | 3.2M | 3.7M | 10.4M | 12.0M | 15.1M | |
| Total Operating Expenses | 29.4M | 40.7M | 39.0M | 7.5M | 8.6M | 15.6M | |
| Income Before Tax | (28.7M) | (41.9M) | (29.9M) | (14.0M) | (12.6M) | (13.3M) | |
| Total Other Income Expense Net | 179.7K | (2.4M) | 15.1K | 539.2K | 485.2K | 509.5K | |
| Net Income | (28.5M) | (41.9M) | (29.9M) | (14.0M) | (12.6M) | (13.3M) | |
| Income Tax Expense | (179.7K) | (5.7K) | (15.1K) | 3.7K | 3.3K | 3.1K | |
| Net Income From Continuing Ops | (28.7M) | (41.9M) | (29.9M) | (24.5M) | (22.1M) | (23.2M) | |
| Net Income Applicable To Common Shares | (148.0M) | (21.4M) | (28.7M) | (41.9M) | (37.7M) | (39.6M) | |
| Net Interest Income | 148.7K | 5.7K | 248.1K | 447.2K | 514.3K | 343.6K | |
| Interest Income | 148.7K | 5.7K | 248.1K | 447.2K | 402.5K | 291.5K |
Additional Tools for Marker Stock Analysis
When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.